Quercetin/oleic acid-based G-protein-coupled receptor 40 ligands as new insulin secretion modulators

Future Medicinal Chemistry

Volumn 9, Issue 16, 2017, Pages 1873-1885

  Badolato, Mariateresa ^a   Carullo, Gabriele ^a   Perri, Mariarita ^a   Cione, Erika ^a   Manetti, Fabrizio ^b   Di Gioia, Maria Luisa ^a   Brizzi, Antonella ^b   Caroleo, Maria Cristina ^a   Aiello, Francesca ^a  

^a Dipartimento di Farmacia and Scienze della Salute and della Nutrizione   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

antidiabetic drugs; GPR40 molecular docking; insulin secretion; quercetin oleic acid based hybrid molecules

Indexed keywords

2 (2,2 DIPHENYLBENZO[D][1,3]DIOXOL 5 YL) 3,5,7 TRIHYDROXY 4H CHROMEN 4 ONE; 2 (2,2 DIPHENYLBENZO[D][1,3]DIOXOL 5 YL) 5 HYDROXY 4 OXO 4H CHROMENE 3,7 DIYL DIOLEATE; 2 (2,2 DIPHENYLBENZO[D][1,3]DIOXOL 5 YL) 5,7 DIHYDROXY 4 OXO 4H CHROMEN 3 YL OLEATE; G PROTEIN COUPLED RECEPTOR 40; OLEIC ACID; QUERCETIN; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; BENZOPYRAN DERIVATIVE; G PROTEIN COUPLED RECEPTOR; INSULIN; LIGAND;

ARTICLE; BLOOD LEVEL; CELL CULTURE; COLUMN CHROMATOGRAPHY; GLUCOSE ABSORPTION; HUMAN; INSULIN RELEASE; LACTIC ACIDOSIS; LIPOTOXICITY; MOLECULAR DOCKING; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; C57BL MOUSE; CELL LINE; CHEMISTRY; COMPUTER SIMULATION; DRUG EFFECT; MALE; METABOLISM; MOUSE; PANCREAS; SYNTHESIS;

ANIMALS; BENZOPYRANS; CELL LINE; COMPUTER SIMULATION; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIGANDS; MALE; MICE; MICE, INBRED C57BL; OLEIC ACID; PANCREAS; QUERCETIN; RECEPTORS, G-PROTEIN-COUPLED;

EID: 85034622413     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc-2017-0113     Document Type: Article

References (61)

1. Perri M, Caroleo MC, Liu N et al. 9-cis retinoic acid modulates myotrophin expression and its miR in physiological and pathophysiological cell models. Exp. Cell. Res. 354(1), 25-30 (2017).
2. Rutter GA, Pullen TJ, Hodson DJ, Martinez-Sanchez A. Pancreatic cell identity, glucose sensing and the control of insulin secretion. Biochem. J. 466(2), 203-218 (2015).
3. Röder PV, Wu B, Liu Y, Han W. Pancreatic regulation of glucose homeostasis. Exp. Mol. Med. 48(3), e219 (2016).
4. Paulweber B, Valensi P, Lindström J et al. A European evidence-based guideline for the prevention of Type 2 diabetes. Horm. Metab. Res. 42(1), S3-S36 (2010).
5. Aschner PM, Muñoz OM, Girón D et al. Clinical practice guideline for the prevention, early detection, diagnosis, management and follow-up of Type 2 diabetes mellitus in adults. Colomb. Med. (Cali.) 47(2), 109-131 (2016).
6. Siavash M, Tabbakhian M, Sabzghabaee AM, Razavi N. Severity of gastrointestinal side effects of metformin tablet compared to metformin capsule in Type 2 diabetes mellitus patients. J. Res. Pharm. Pract. 6(2), 73-76 (2017).
7. Vasapollo P, Cione E, Luciani F, Gallelli L. Generalized intense pruritus during canagliflozin treatment: is it an adverse drug reaction? Curr. Drug Saf. doi:10.2174/1574886311666160405110515 (2016) (Epub ahead of print).
8. Chaudhury A, Duvoor C, Reddy Dendi VS et al. Clinical review of antidiabetic drugs: implications for Type 2 diabetes mellitus management. Front. Endocrinol. 8, 6 (2017).
9. Vinayagam R, Xiao J, Xu B. An insight into anti-diabetic properties of dietary phytochemicals. Phytochem. Rev. 16(3), 535-553 (2017).
10. Carullo G, Cappello AR, Frattaruolo L, Badolato M, Armentano B, Aiello F. Quercetin and derivatives: useful tools in inflammation and pain management. Future Med. Chem. 9(1), 79-93 (2017).
11. D'Andrea G. Quercetin: a flavonol with multifaceted therapeutic applications? Fitoterapia 106, 256-271 (2015).
12. Vinayagam R, Xu B. Antidiabetic properties of dietary flavonoids: a cellular mechanism review. Nutr. Metab. 12, 60 (2015).
13. Wach A, Pyrzýnska K, Biesaga M. Quercetin content in some food and herbal samples. Food Chem. 100(2), 699-704 (2007).
14. Mukhopadhyay P, Prajapati AK. Quercetin in anti-diabetic research and strategies for improved quercetin bioavailability using polymer-based carriers-a review. RSC Adv. 5, 97547-97562 (2015).
15. Pilichiewicz A, O'Donovan D, Feinle C et al. Effect of lipase inhibition on gastric emptying of, and the glycemic and incretin responses to, an oil/aqueous drink in Type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 88(8), 3829-3834 (2003).
16. Perez-Martinez P, Garcia-Rios A, Delgado-Lista J, Perez-Jimenez F, Lopez-Miranda J. Mediterranean diet rich in olive oil and obesity, metabolic syndrome and diabetes mellitus. Curr. Pharm. Des. 17(8), 769-777 (2011).
17. Boskou D, Blekas G, Tsimidou M. Olive oil composition. In: Olive Oil Chemistry and Technology (2nd Edition). Boskou D (Ed.). Elsevier: Academic Press and AOCS Press, Amsterdam, the Netherlands, 282 (2006).
18. Santos LRB, Rebelato E, Graciano MFR, Abdulkader F, Curi R, Carpinelli AR. Oleic acid modulates metabolic substrate channeling during glucose-stimulated insulin secretion via NAD(P)H oxidase. Endocrinology 152(10), 3614-3621 (2011).
19. Ferdaoussi M, Bergeron V, Zarrouki B et al. G protein-coupled receptor (GPR)40-dependent potentiation of insulin secretion in mouse islets is mediated by protein kinase D1. Diabetologia 55(10), 2682-2692 (2012).
20. McKillop AM, Moran BM, Abdel-Wahab YHA, Flatt PR. Evaluation of the insulin releasing and antihyperglycaemic activities of GPR55 lipid agonists using clonal beta-cells, isolated pancreatic islets and mice. Br. J. Pharmacol. 170(5), 978-990 (2013).
21. Liu B, Hassan Z, Amisten S et al. The novel chemokine receptor, G-protein-coupled receptor 75, is expressed by islets and is coupled to stimulation of insulin secretion and improved glucose homeostasis. Diabetologia 56(11), 2467-2476 (2013).
22. Barton M, Prossnitz ER. Emerging roles of GPER in diabetes and atherosclerosis. Trends Endocrinol. Metab. 26(4), 185-192 (2015).
23. Tiano JP, Delghingaro-Augusto V, Le May C et al. Estrogen receptor activation reduces lipid synthesis in pancreatic islets and prevents cell failure in rodent models of Type 2 diabetes. J. Clin. Invest. 121(8), 3331-3342 (2011).
24. Aiello F, Carullo G, Giordano F et al. Identification of breast cancer inhibitors specific for G protein-coupled estrogen receptor (GPER)-expressing cells. ChemMedChem 12, 1-8 (2017).
25. Itoh Y, Kawamata Y, Harada M et al. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature 422, 173-176 (2003).
26. Schnell S, Schaefer M, Schöfl C. Free fatty acids increase cytosolic free calcium and stimulate insulin secretion from cells through activation of GPR40. Mol. Cell. Endocrinol. 263, 173-180 (2007).
27. Yashiro H, Tsujihata Y, Takeuchi K, Hazama M, Johnson PR, Rorsman P. The effects of TAK-875, a selective G protein-coupled receptor 40/free fatty acid 1 agonist, on insulin and glucagon secretion in isolated rat and human islets. J. Pharmacol. Exp. Ther. 340, 483-489 (2012).
28. Araki T, Hirayama M, Hiroi S, Kaku K. GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with Type 2 diabetes. Diabetes Obes. Metab. 14, 271-278 (2012).
29. Srivastava A, Yano J, Hirozane Y et al. High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875. Nature 513, 124-127 (2014).
30. Chen C, Li H, Long Y. GPR40 agonists for the treatment of Type 2 diabetes mellitus: The biological characteristics and the chemical space. Bioorg. Med. Chem. Lett. 26(23), 5603-5612 (2016).
31. Li H, Huang Q, Chen C, Xu B, Wang H. Long Y discovery of potent and orally bioavailable GPR40 full agonists bearing thiophen-2-ylpropanoic acid scaffold. J. Med. Chem. 60, 2697-2717 (2017).
32. Jurica EA, Wu X, Williams KN et al. Discovery of pyrrolidine-containing GPR40 agonists: stereochemistry effects a change in binding mode. J. Med. Chem. 60, 1417-1431 (2017).
33. Yang J, Li Z, Li H et al. Design, synthesis and structure-activity relationship studies of novel free fatty acid receptor 1 agonists bearing amide linker. Bioorg. Med. Chem. 25, 2445-2450 (2017).
34. Krasavin M, Lukin A, Bagnyukova D et al. Free fatty acid receptor 1 (GPR40) agonists containing spirocyclic periphery inspired by LY2881835. Bioorg. Med. Chem. 24, 5481-5494 (2016).
35. Krasavin M, Lukin A, Zhurilo A et al. Novel free fatty acid receptor 1 (GPR40) agonists based on 1,3,4-thiadiazole-2-carboxamide scaffold. Bioorg. Med. Chem. 24, 2954-2963 (2016).
36. Defossa E, Wagner M. Recent developments in the discovery of FFA1 receptor agonists as novel oral treatment for type 2 diabetes mellitus. Bioorg. Med. Chem. Lett. 24, 2991-3000 (2014).
37. Milligan G, Alvarez-Curto E, Watterson KR, Ulven T, Hudson BD. Characterizing pharmacological ligands to study the long-chain fatty acid receptors GPR40/FFA1 and GPR120/FFA4. Br. J. Pharmacol. 172, 3254-3265 (2015).
38. Watterson KR, Hudson BD, Ulven T, Milligan G. Treatment of Type 2 diabetes by free fatty acid receptor agonists. Front. Endocrinol. 5, 137 (2014).
39. Lin DCH, Guo Q, Luo J et al. Identification and pharmacological characterization of multiple allosteric binding sites on the free fatty acid 1 receptor. J. Mol. Pharm. 82, 843-859 (2012).
40. Christiansen E, Watterson KR, Stocker CJ et al. Activity of dietary fatty acids on FFA1 and FFA4 and characterisation of pinolenic acid as a dual FFA1/FFA4 agonist with potential effect against metabolic diseases. Br. J. Nutr. 113, 1677-1688 (2015).
41. Tikhonova IG, Poerio E. Free fatty acid receptors: structural models and elucidation of ligand binding interactions. BMC Struct. Biol. 15, 16 (2015).
42. Fujiwara K, Maekawa F, Yada T. Oleic acid interacts with GPR40 to induce Ca2+ signaling in rat islet cells: mediation by PLC and L-type Ca2+ channel and link to insulin release. Am. J. Physiol. Endocrinol. Metab. 289(4), E670-E677 (2005).
43. Elias S, Wisam S, Luai A, Massad B, Nimer A. Lipotoxicity in obesity: benefit of olive oil. In: Obesity and Lipotoxicity, Advances in Experimental Medicine and Biology 960. Engin AB, Engin A (Eds.), Springer International Publishing AG, Gewerbestrasse, Switzerland (2017).
44. Youl E, Bardy G, Magous R et al. Quercetin potentiates insulin secretion and protects INS-1 pancreatic cells against oxidative damage via the ERK1/2 pathway. Br. J. Pharmacol. 161, 799-814 (2010).
45. Kim MK, Park K, Lee C, Park HR, Choo Hyunah, Chong Y. Enhanced stability and intracellular accumulation of quercetin by protection of the chemically or metabolically susceptible hydroxyl groups with a pivaloxymethyl (POM) promoiety. J. Med. Chem. 53, 8597-8607 (2010).
46. Zhou A, Kikandi S, Sadik OA. Electrochemical degradation of quercetin: isolation and structural elucidation of the degradation products. Electrochem. Commun. 9, 2246-2255 (2007).
47. Trouillas P, Marsal P, Siri D, Lazzaroni R, Duroux J. A DFT study of the reactivity of OH groups in quercetin and taxifolin antioxidants: the specificity of the 3-OH site. Food Chem. 97, 679-688 (2006).
48. Saija A, Tomaino A, Trombetta D et al. 'In vitro' antioxidant and photoprotective properties and interaction with model membranes of three new quercetin esters. Eur. J. Pharm. Biopharm. 56, 167-174 (2003).
49. Hohmeier HE, Mulder H, Chen G, Henkel-Rieger R, Prentki M, Newgard CB. Isolation of INS-1-derived cell lines with robust ATP-sensitive K+ channel-dependent and-independent glucose-stimulated insulin secretion. Diabetes 49(3), 424-430 (2000).
50. Hectors TLM, Vanparys C, Pereira-Fernandes A, Martens GA, Blust R. Evaluation of the INS-1 832/13 cell line as a beta-cell based screening system to assess pollutant effects on beta-cell function. PLoS ONE 8(3), e60030 (2013).
51. Kane MA, Folias AE, Pingitore A et al. Identification of 9-cis-retinoic acid as a pancreas-specific autacoid that attenuates glucose-stimulated insulin secretion. Proc. Natl Acad. Sci. USA 107(50), 21884-21889 (2010).
52. Li N, Shi Z, Tang Y, Yang J, Duan J. An efficient partial synthesis of 4-O-methylquercetin via regioselective protection and alkylation of quercetin. Beilstein J. Org. Chem. 5, 60 (2009).
53. Schrödinger, LLC, www.schrodinger.com
54. Montana E, Bonner-Weir S, Weir GC. Beta cell mass and growth after syngeneic islet cell transplantation in normal and streptozocin diabetic C57BL/6 mice. J. Clin. Invest. 91, 780 (1993).
55. Mainini F, Contini A, Nava D et al. Synthesis, molecular characterization and preliminary antioxidant activity evaluation of quercetin fatty esters. J. Am. Oil. Chem. Soc. 90, 1751-1759 (2013).
56. McGarry JD, Dobbins RL. Fatty acids, lipotoxicity and insulin secretion. Diabetologia 42, 128-138 (1999).
57. Bardy G, Virsolvy A, Quignard JF et al. Quercetin induces insulin secretion by direct activation of L-type calcium channels in pancreatic beta cells. Br. J. Pharmacol. 169, 1102-1113 (2013).
58. Zhang Y, Meifang X, Niu G, Tan H. Mechanisms of oleic acid deterioration in insulin secretion: role in the pathogenesis of Type 2 diabetes. Life Sci. 77(17), 2071-2081 (2005).
59. Biasutto L, Marotta E, De Marchi U, Zoratti M, Paradisi C. Ester-based precursors to increase the bioavailability of quercetin. J. Med. Chem. 50, 241-253 (2007).
60. Shia C, Tsai S, Kuo S, Hou Y, Lee Chao P. Metabolism and pharmacokinetics of 3,3-,4-,7-tetrahydroxyflavone (fisetin), 5-hydroxyflavone, and 7-hydroxyflavone and antihemolysis effects of fisetin and its serum metabolites. J. Agric. Food Chem. 57, 83-89 (2009).
61. Chen Y, Xiao P, Ou-Yang D et al. Simultaneous action of the flavonoid quercetin on cytochrome P450 (CYP) 1A2, CYP2A6, N-acetyltransferase and xanthine oxidase activity in healthy volunteers. Clin. Exp. Pharmacol. Physiol. 36(8), 828-833 (2009).